Key US Advisory Committee to Vote on Changing Newborn Hepatitis B Vaccine Recommendation

Following a hold-up and a particularly heated meeting, a government vaccine expert group was set to cast ballots on Friday regarding a potential change to the enduring advisory that every infant be immunized against hepatitis B.

Fiery Exchange and a Delayed Ballot

The opening session of the conference on Thursday was defined by fiery discussion over limiting availability to the hepatitis B vaccine for infants and a resolution to delay the ballot by a day to allow panelists additional time to examine the language. The panel, which guides the CDC on immunization practices, had put off the vote twice in the past.

“Is there any concrete proof of injury of giving this shot before 30 days? Or is this speculation?” asked one adviser.

In answer, another member stated, “There is inadequate data about the enduring danger.”

Present Protocol and Potential Impact

The vaccine is currently suggested for all infants within 24 hours of being born to stop transmission of hepatitis B, which can lead to serious liver damage. It has been administered to more than a billion persons for in excess of thirty years.

The Atlanta conference provided no fresh data of harms caused by the vaccine. Experts say any modification to the present hepatitis B immunization timeline could have significant and far-reaching consequences for infant and child health in the United States.

Panel Composition and Latest Shifts

The expert committee can only offer guidance to the director of the CDC. The panel's membership has seen shifts this week, with the statement that the group's former head would step down for an formal position and be succeeded by a cardiac doctor who has been questioning of other immunizations.

The board includes several vaccination critics who are in agreement with a desire to overhaul – and potentially, in some cases, abolish – long-established vaccine advisories.